Biotech shareholders don't want to sell at bargain prices. Pharma doesn't want to pay big premiums. Who's going to prevail? Report
Biotech shareholders don't want to sell at bargain prices. Pharma doesn't want to pay big premiums. Who's going to prevail? Report